Clinical and Economic Impact of Nirsevimab and Bivalent Maternal Vaccine Against RSV Infections in Infants in Italy

Chiara Bini, Andrea Marcellusi, Barbara Muzii, Samira Soudani, Sara Trotta, Salvatore Parisi, Elena Bozzola, Paolo Bonanni, Sara Boccalini

Open source

DOI
10.2147/ceor.s622013
Published
2026-11
Container
ClinicoEconomics and Outcomes Research
Publisher
Informa UK Limited
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.2147/ceor.s622013,
  title = {Clinical and Economic Impact of Nirsevimab and Bivalent Maternal Vaccine Against RSV Infections in Infants in Italy},
  author = {Chiara Bini and Andrea Marcellusi and Barbara Muzii and Samira Soudani and Sara Trotta and Salvatore Parisi and Elena Bozzola and Paolo Bonanni and Sara Boccalini},
  year = {2026},
  journal = {ClinicoEconomics and Outcomes Research},
  doi = {10.2147/ceor.s622013},
  url = {https://doi.org/10.2147/ceor.s622013}
}

RIS

TY  - JOUR
TI  - Clinical and Economic Impact of Nirsevimab and Bivalent Maternal Vaccine Against RSV Infections in Infants in Italy
AU  - Chiara Bini
AU  - Andrea Marcellusi
AU  - Barbara Muzii
AU  - Samira Soudani
AU  - Sara Trotta
AU  - Salvatore Parisi
AU  - Elena Bozzola
AU  - Paolo Bonanni
AU  - Sara Boccalini
PY  - 2026
JO  - ClinicoEconomics and Outcomes Research
DO  - 10.2147/ceor.s622013
UR  - https://doi.org/10.2147/ceor.s622013
ER  - 

APA

Bini, C., Marcellusi, A., Muzii, B., Soudani, S., Trotta, S., Parisi, S., Bozzola, E., Bonanni, P., & Boccalini, S. (2026). Clinical and Economic Impact of Nirsevimab and Bivalent Maternal Vaccine Against RSV Infections in Infants in Italy. ClinicoEconomics and Outcomes Research. https://doi.org/10.2147/ceor.s622013

Source records